Home » Topics » Disease categories and therapies » Respiratory

Respiratory
RSS

HMR claims dual H1/NK1 antagonists for allergic/inflammatory disorders

Nov. 4, 1997

rPAF-AH proceeds to phase II for asthma

Oct. 31, 1997

HMR reports dual H1/NK1 receptor antagonists

Oct. 30, 1997

Spotlight on tryptase inhibitors for asthma

Oct. 28, 1997

SciClone presents promising preclinical data for CPX at CF conference

Oct. 27, 1997

Potent, topically active glucocorticoid from RPR shows potential for bronchial asthma

Oct. 24, 1997

Abbott develops inhibitors of LT biosynthesis

Oct. 24, 1997

TBC-1269 enters phase II for treatment and prevention of asthma

Oct. 24, 1997

Oxis Turbuhaler launched in U.K.

Oct. 23, 1997

Bradykinin antagonists from Pfizer

Oct. 23, 1997

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 24, 2026.
Detecting the invisible: minimal residual disease at AACR 2026
BioWorld Science
Minimal residual disease (MRD) has become a central concept in modern oncology, reshaping how clinicians evaluate response, relapse risk and treatment precision....
A free gene therapy? Regeneron’s Otarmeni approved for hearing loss
BioWorld
Children and adults with a type of congenital hearing loss now have a free treatment option, with the U.S. FDA’s accelerated approval of Regeneron Pharmaceuticals...
AACR 2026: The age of agentic AI in oncology
BioWorld Science
New Approach Methodologies (NAMs) for drug development are transforming biomedical research by replacing or complementing animal models. More than 90% of...
Chengdu Mfs Pharma synthesizes new compounds for pain
BioWorld Science
Chengdu Mfs Pharma Co. Ltd. has prepared and tested compounds for the potential treatment of pain, sleep disorder and status epilepticus epilepsy as well as for...